Marengo: Bold Moves in TMB-H Tumor Treatment
A New Hope for Tough Tumors? Marengo Therapeutics is stirring up the oncology world with some intriguing Phase 2 results from their STARt-001 clinical trial, revealing invikafusp alfa's potential as a single-agent therapy. This hasn’t been a walk in the park, mind you; we're talking about dealing with TMB-H solid tumors that typically thumb their noses at immune...
Continue Reading